Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.

Approximately 20% to 25% of patients with acute myeloid leukemia (AML) have a constitutively activated FLT3-internal tandem duplication (FLT3-ITD), and these patients exhibit a poor prognosis. Here, we report that Axl, a receptor tyrosine kinase (RTK) overexpressed and constitutively active in human AML, targets the RTK FLT3 in FLT3-ITD(+) AML. Abrogation of Axl activation by soluble Axl chimeric protein (Axl-Fc) or small interfering RNA (siRNA) diminishes constitutive FLT3 phosphorylation in FLT3-ITD(+) AML. In addition, inhibition of Axl activation by Axl-Fc interferes with the physical interaction between Axl and FLT3. We found that Axl-Fc, a pharmacologic Axl inhibitor, or siRNA targeting Axl inhibits cell growth, induces cell-cycle arrest and apoptosis, and relieves a block in myeloid differentiation of FLT3-ITD(+) AML in vitro. Axl-Fc also suppresses the growth of human FLT3-ITD(+) AML in vivo. Collectively, our data suggest that Axl contributes to the pathogenesis of FLT3-ITD(+) AML through, at least in part, positive regulation of constitutive FLT3 activation. This also suggests that Axl should be pursued as a potential target for the treatment of FLT3-ITD(+) AML.

[1]  G. Shapiro,et al.  A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 , 2010, Clinical Cancer Research.

[2]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[3]  H. Hanafusa,et al.  Identification of the Product of Growth Arrest-specific Gene 6 as a Common Ligand for Axl, Sky, and Mer Receptor Tyrosine Kinases* , 1996, The Journal of Biological Chemistry.

[4]  T. Tamaya,et al.  Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  D. Mukhopadhyay,et al.  The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. , 2011, Blood.

[6]  R. Herrmann,et al.  Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) , 1999, Leukemia.

[7]  D. Tenen,et al.  Phosphorylation of C/EBPalpha inhibits granulopoiesis. , 2004, Molecular and cellular biology.

[8]  B. Dahlbäck,et al.  Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. , 2006, Cytokine & growth factor reviews.

[9]  R. Seitz,et al.  Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells , 1999, Cancer.

[10]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[11]  D. Hicklin,et al.  FLT 3 ligand causes autocrine signaling in acute myeloid leukemia cells , 2003 .

[12]  R. Weimer,et al.  An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies , 2010, Oncogene.

[13]  Daniel G. Tenen,et al.  Transcription factors in myeloid development: balancing differentiation with transformation , 2007, Nature Reviews Immunology.

[14]  D. Hicklin,et al.  FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. , 2004, Blood.

[15]  D. Fabbro,et al.  Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412 , 2002 .

[16]  Tina N. Davis,et al.  Proteomic and genetic approaches identify Syk as an AML target. , 2009, Cancer cell.

[17]  D. Tenen,et al.  Phosphorylation of C/EBPα Inhibits Granulopoiesis , 2004, Molecular and Cellular Biology.

[18]  G. Marcucci,et al.  implications for Axl as a potential therapeutic target FLT3 internal tandem duplication in human acute myeloid leukemia: Inhibition of the receptor tyrosine kinase Axl impedes activation of the , 2013 .

[19]  R. Scott,et al.  Phagocytosis and clearance of apoptotic cells is mediated by MER , 2001, Nature.

[20]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[21]  Li Yang,et al.  Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up‐regulates phospholipid scramblase 1 gene expression , 2008, Cancer science.

[22]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[23]  K. Yamaguchi,et al.  Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. , 2009, Cancer research.

[24]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[25]  Kyu-Tae Kim,et al.  Constitutively activated FLT3 phosphorylates BAD partially through Pim‐1 , 2006, British journal of haematology.

[26]  Kevin Wei,et al.  AXL is an essential factor and therapeutic target for metastatic ovarian cancer. , 2010, Cancer research.

[27]  M. Caligiuri,et al.  The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. , 2009, Blood.

[28]  D. Huhn,et al.  Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. , 1994, Blood.

[29]  N. Gray,et al.  FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[30]  Y. Hitoshi,et al.  R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.

[31]  D. Steinbach,et al.  Clinical implications of c-Kit mutations in acute myelogenous leukemia , 2009, Current hematologic malignancy reports.

[32]  G. Lemke,et al.  TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response , 2007, Cell.

[33]  S. Goff,et al.  Tyro-3 family receptors are essential regulators of mammalian spermatogenesis , 1999, Nature.

[34]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[35]  M. Schott.  Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer , 2011 .

[36]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[37]  H. Drexler,et al.  Expression of the growth arrest-specific gene 6 (GAS6) in leukemia and lymphoma cell lines. , 1999, Leukemia research.

[38]  S. Bohlander,et al.  Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations , 2006, The Journal of experimental medicine.

[39]  S. Knapper.  FLT3 inhibition in acute myeloid leukaemia , 2007, British journal of haematology.

[40]  H. Snodgrass,et al.  Cloning and Mrna Expression Analysis of a Novel Human Protooncogene, C-merr , 2022 .

[41]  S. Grant,et al.  Exploiting cellular pathways to develop new treatment strategies for AML. , 2010, Cancer treatment reviews.

[42]  D. Small,et al.  Mutant FLT3 signaling contributes to a block in myeloid differentiation , 2005, Leukemia & lymphoma.

[43]  B. Dahlbäck,et al.  Gas6 and protein S , 2006, The FEBS journal.

[44]  M. Levis,et al.  Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. , 2004, Blood.

[45]  H. Drexler,et al.  Differential expression of the ufo/axl oncogene in human leukemia-lymphoma cell lines. , 1996, Leukemia.